Cinclus Pharma Holding AB (publ) (CINPHA.ST) — Stock Score Summary

Cinclus Pharma Holding AB (publ) (CINPHA.ST) has a MoatMap StockRank of 10/100 based on Quality (28/100), Value (38/100), and Momentum (26/100) factor scores. The current signal is STRONG SELL. Cinclus Pharma is a clinical-stage Swedish biotech with no commercialized products, high cash burn, and no alignment with our CDMO manufacturing theme.

Cinclus Pharma Holding AB is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for severe acid-related gastrointestinal diseases. Its lead candidate, linaprazan glurate, is a potassium-competitive acid blocker (P-CAB) designed to provide faster, more effective, and longer-lasting acid control than standard proton pump inhibitors (PPIs). The company targets a multi-billion-dollar global market for gastroesophageal reflux disease (GERD), backed by robust Phase II clinical data and strong patent protection.

Key Financial Metrics

Price$1.29
Market Cap$61M
P/E (Forward)-2.14
Price/Book2.00
Return on Equity-60.3%
Return on Invested Capital-44.7%
Debt/Equity18.83
Gross Margin100.0%
Operating Margin-905.3%
Free Cash Flow$-718K

Cinclus Pharma Holding AB (publ) operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (Sweden).

Frequently Asked Questions

What is Cinclus Pharma Holding AB (publ)’s (CINPHA.ST) StockRank?
MoatMap’s StockRank for Cinclus Pharma Holding AB (publ) (CINPHA.ST) is 10/100, with a Strong Sell signal. It is a composite of Quality (28), Value (38), and Momentum (26) factor ranks across MoatMap’s 19,000+ stock universe.
Does Cinclus Pharma Holding AB (publ) have an economic moat?
Cinclus Pharma Holding AB (publ) (CINPHA.ST) has a Quality factor score of 28/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Cinclus Pharma Holding AB (publ) a buy, hold, or sell?
MoatMap’s current signal for Cinclus Pharma Holding AB (publ) (CINPHA.ST) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Cinclus Pharma Holding AB (publ) in?
Cinclus Pharma Holding AB (publ) (CINPHA.ST) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (Sweden).
Browse all ranked stocksCINPHA.ST deep dive reportAI ChampionsHow we score stocksSense-check another stock